Shoujun Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shoujun Bai has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Tingting Ji
Department of Nephrology
14 shared publicationsBo Tang
Department of Nephrology Qingpu Branch of Zhongshan Hospital Fudan University Shanghai China
12 shared publicationsXiaoying Li
Department of Nephrology
8 shared publicationsXiaolei Qu
Department of Nephrology
7 shared publicationsJi Li
Department of Nephrology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, 1158 Gongyuan East Road, Qingpu District, Shanghai 201700, China
6 shared publicationsWeiliang Li
Department of Urology
6 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1)
A study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis
1. Diabetic nephropathy (DN) is one of the most common and severe chronic complications of diabetes and a leading cause of end‑stage renal disease (ESRD) and renal failure. As the global prevalence...
- 5 August 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1)
Open AccessA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis
1. Diabetic nephropathy (DN) is one of the most common and severe chronic complications of diabetes and a leading cause of end‑stage renal disease (ESRD) and renal failure. As the global prevalence...
- Open Access
- 3 June 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (2) , 1-12
β‑elemene attenuates IRI‑AKI by inhibiting inflammation and apoptosis via suppression of the TLR4/MyD88/NF‑κB/MAPK signal axis activation
Ischemia‑reperfusion injury‑induced acute kidney injury (IRI‑AKI) involves inflammatory cell infiltration and increased apoptosis, although the potential association between these processes remains unclear. The aim of the present study was to assess the impact of β‑elemene treatment on the IRI‑AKI using both in vivo and in vitro models, reverse transcription‑quantitative PCR, western blot assays, hematoxylin and Eosin (H&E) staining, Immunohistochemical staining and TUNEL staining. β‑elemene significantly decreased morphological and pathological kidney inflammation in mice caused by IRI. Additionally, β‑elemene prevented the expression of inflammatory factors and apoptosis proteins dose‑dependently in IRI mice and rat renal proximal tubule NRK52E cells treated with H2O2. Mechanistically, β‑elemene exerted its effects by inhibiting toll‑like receptor 4/myeloid differentiation primary response gene 88 (MyD88) signal activation and blocking NF‑κB/MAPK signal phosphorylation. Additionally, the increases in apoptosis and MAPK signal activation following hydrogen peroxide treatment were restored by MyD88 inhibition in NRK52E cells. The present study revealed that β‑elemene is a promising preclinical candidate for AKI.
- 3 June 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (2) , 1-12
Open Accessβ‑elemene attenuates IRI‑AKI by inhibiting inflammation and apoptosis via suppression of the TLR4/MyD88/NF‑κB/MAPK signal axis activation
Ischemia‑reperfusion injury‑induced acute kidney injury (IRI‑AKI) involves inflammatory cell infiltration and increased apoptosis, although the potential association between these processes remains unclear. The aim of the present study was to assess the impact of β‑elemene treatment on the IRI‑AKI using both in vivo and in vitro models, reverse transcription‑quantitative PCR, western blot assays, hematoxylin and Eosin (H&E) staining, Immunohistochemical staining and TUNEL staining. β‑elemene significantly decreased morphological and pathological kidney inflammation in mice caused by IRI. Additionally, β‑elemene prevented the expression of inflammatory factors and apoptosis proteins dose‑dependently in IRI mice and rat renal proximal tubule NRK52E cells treated with H2O2. Mechanistically, β‑elemene exerted its effects by inhibiting toll‑like receptor 4/myeloid differentiation primary response gene 88 (MyD88) signal activation and blocking NF‑κB/MAPK signal phosphorylation. Additionally, the increases in apoptosis and MAPK signal activation following hydrogen peroxide treatment were restored by MyD88 inhibition in NRK52E cells. The present study revealed that β‑elemene is a promising preclinical candidate for AKI.
- Open Access
- 2 December 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (1) , 151-162
Exosomal hsa_circ_0125310 promotes cell proliferation and fibrosis in diabetic nephropathy via sponging miR‐422a and targeting the IGF1R/p38 axis
Diabetic nephropathy (DN) is still on the rise worldwide, and millions of patients have to be treated through dialysis or transplant because of kidney failure caused by DN. Recent reports have highlighted circRNAs in the treatment of DN. Herein, we aimed to investigate the mechanism by which high glucose‐induced exo‐circ_0125310 promotes diabetic nephropathy progression. circ_0125310 is highly expressed in diabetic nephropathy and exosomes isolated from high glucose‐induced mesangial cells (MCs). High glucose‐induced exosomes promote the proliferation and fibrosis of MCs. However, results showed that the effects of exosomes on MCs can be reversed by the knockdown of circ_0125310. miR‐422a, which targets IGF1R, was the direct target of circ_0125310. circ_0125310 regulated IGF1R/p38 axis by sponging miR‐422a. Exo‐circ_0125310 increased the luciferase activity of the WT‐IGF1R reporter in the dual‐luciferase reporter gene assays and upregulated the expression level of IGF1R and p38. Finally, in vivo research indicated that the overexpression of circ_0125310 promoted the diabetic nephropathy progression. Above results demonstrated that the high glucose‐induced exo‐circ_0125310 promoted cell proliferation and fibrosis in diabetic nephropathy via sponging miR‐422a and targeting the IGF1R/p38 axis.
- 2 December 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (1) , 151-162
Open AccessExosomal hsa_circ_0125310 promotes cell proliferation and fibrosis in diabetic nephropathy via sponging miR‐422a and targeting the IGF1R/p38 axis
Diabetic nephropathy (DN) is still on the rise worldwide, and millions of patients have to be treated through dialysis or transplant because of kidney failure caused by DN. Recent reports have highlighted circRNAs in the treatment of DN. Herein, we aimed to investigate the mechanism by which high glucose‐induced exo‐circ_0125310 promotes diabetic nephropathy progression. circ_0125310 is highly expressed in diabetic nephropathy and exosomes isolated from high glucose‐induced mesangial cells (MCs). High glucose‐induced exosomes promote the proliferation and fibrosis of MCs. However, results showed that the effects of exosomes on MCs can be reversed by the knockdown of circ_0125310. miR‐422a, which targets IGF1R, was the direct target of circ_0125310. circ_0125310 regulated IGF1R/p38 axis by sponging miR‐422a. Exo‐circ_0125310 increased the luciferase activity of the WT‐IGF1R reporter in the dual‐luciferase reporter gene assays and upregulated the expression level of IGF1R and p38. Finally, in vivo research indicated that the overexpression of circ_0125310 promoted the diabetic nephropathy progression. Above results demonstrated that the high glucose‐induced exo‐circ_0125310 promoted cell proliferation and fibrosis in diabetic nephropathy via sponging miR‐422a and targeting the IGF1R/p38 axis.
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1) , 8814163
hsa‐miR‐199b‐3p Prevents the Epithelial‐Mesenchymal Transition and Dysfunction of the Renal Tubule by Regulating E‐cadherin through Targeting KDM6A in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of end‐stage renal disease. The association between epithelial‐mesenchymal transition (EMT) and fibrosis is quite ascertained, but its link to eventual tubule dysfunction is missing. Here, we show that human microRNA‐ (hsa‐miR‐) 199b‐3p protects renal tubules from diabetic‐induced injury by repressing KDM6A, a histone lysine demethylase regulating E‐cadherin expression. Lower E‐cadherin expression is related to a higher level of KDM6A, while E‐cadherin is promoted upon treatment with the KDM6A inhibitor GSK‐J4 in both high glucose‐ (HG‐) induced HK2 cells and the kidneys from streptozotocin‐ (STZ‐) induced type 1 diabetic mice. However, overexpression or RNA silencing of E‐cadherin fails to alter KDM6A expression. We also show that the upregulation of KDM6A is associated with the increased methylation level of the E‐cadherin promoter. Then, the target prediction results and a dual‐luciferase assay show that hsa‐miR‐199b‐3p is a new miRNA that targets KDM6A. Overexpression of hsa‐miR‐199b‐3p increases E‐cadherin expression and prevents EMT through repressing KDM6A expression in HG‐induced HK2 cells. In contrast, inhibitor‐induced hsa‐miR‐199b‐3p knockdown has opposite effects, as it decreases E‐cadherin level and worsens EMT, accompanied by increased levels of KDM6A. Besides, Mir199b‐knockout mice without mmu‐miR‐119b‐3p expression exhibit more renal tubule dysfunction and more serious kidney tissue damage upon treatment with STZ. These results demonstrate that hsa‐miR‐199b‐3p improves E‐cadherin expression and prevents the progression of DN through targeting KDM6A. miR‐199b‐3p could be a future biomarker or target for the diagnosis or treatment of DN.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1) , 8814163
Open Accesshsa‐miR‐199b‐3p Prevents the Epithelial‐Mesenchymal Transition and Dysfunction of the Renal Tubule by Regulating E‐cadherin through Targeting KDM6A in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of end‐stage renal disease. The association between epithelial‐mesenchymal transition (EMT) and fibrosis is quite ascertained, but its link to eventual tubule dysfunction is missing. Here, we show that human microRNA‐ (hsa‐miR‐) 199b‐3p protects renal tubules from diabetic‐induced injury by repressing KDM6A, a histone lysine demethylase regulating E‐cadherin expression. Lower E‐cadherin expression is related to a higher level of KDM6A, while E‐cadherin is promoted upon treatment with the KDM6A inhibitor GSK‐J4 in both high glucose‐ (HG‐) induced HK2 cells and the kidneys from streptozotocin‐ (STZ‐) induced type 1 diabetic mice. However, overexpression or RNA silencing of E‐cadherin fails to alter KDM6A expression. We also show that the upregulation of KDM6A is associated with the increased methylation level of the E‐cadherin promoter. Then, the target prediction results and a dual‐luciferase assay show that hsa‐miR‐199b‐3p is a new miRNA that targets KDM6A. Overexpression of hsa‐miR‐199b‐3p increases E‐cadherin expression and prevents EMT through repressing KDM6A expression in HG‐induced HK2 cells. In contrast, inhibitor‐induced hsa‐miR‐199b‐3p knockdown has opposite effects, as it decreases E‐cadherin level and worsens EMT, accompanied by increased levels of KDM6A. Besides, Mir199b‐knockout mice without mmu‐miR‐119b‐3p expression exhibit more renal tubule dysfunction and more serious kidney tissue damage upon treatment with STZ. These results demonstrate that hsa‐miR‐199b‐3p improves E‐cadherin expression and prevents the progression of DN through targeting KDM6A. miR‐199b‐3p could be a future biomarker or target for the diagnosis or treatment of DN.
- 1 January 2021
- Vol. 13 (5) , 4296-4308
Ameliorative effects of miR-186 on cisplatin-triggered acute kidney injury via targeting ZEB1
Cisplatin is a commonly used chemotherapy drug in cancers, which can lead to acute kidney injury (AKI). AKI can occur in almost one third of tumor patients, who receive cisplatin treatment. microRNAs (miRNAs) are significant tools in regulating the expression of crucial factors in multiple diseases, but little is known about their biological roles in AKI. As exhibited, miR-186 has been observed to be down-regulated in tumors. Our study concentrated on the function of miR-186 in cisplatin-triggered AKI. Here, we reported miR-186 was considerably decreased in the serum samples from AKI patients compared with those from the healthy controls. Additionally, we found in NRK-52E cells exposed to 6 mM cisplatin, miR-186 was greatly decreased time-dependently. Meanwhile, an AKI model in rats was successfully set in our study. Levels of serum creatinine and blood urea nitrogen were significantly induced by cisplatin exposure. In AKI rat models, miR-186 exhibited a rapid decrease in both the serum and the kidney tissues. Then, miR-186 overexpression improved NRK-52E cell proliferation and protected NRK-52E cells against cisplatin-triggered apoptosis. Furthermore, ZEB1 was identified and confirmed as a target gene of miR-186. It has been demonstrated that ZEB1 exerts crucial roles in the development of AKI. As evidenced in our current study, ZEB1 was remarkably elevated in AKI patients and AKI rat models. Moreover, ZEB1 was induced by indicated doses of cisplatin in different time periods in NRK-52E cells. ZEB1 inhibition rescued the reduced proliferation and increased apoptosis of NRK-52E cells. In conclusion, loss miR-186 expression contributed to cisplatin-induced AKI, partly through targeting ZEB1. miR-186 might be provided as an effective biomarker for AKI via targeting ZEB1.
- 1 January 2021
- Vol. 13 (5) , 4296-4308
Ameliorative effects of miR-186 on cisplatin-triggered acute kidney injury via targeting ZEB1
Cisplatin is a commonly used chemotherapy drug in cancers, which can lead to acute kidney injury (AKI). AKI can occur in almost one third of tumor patients, who receive cisplatin treatment. microRNAs (miRNAs) are significant tools in regulating the expression of crucial factors in multiple diseases, but little is known about their biological roles in AKI. As exhibited, miR-186 has been observed to be down-regulated in tumors. Our study concentrated on the function of miR-186 in cisplatin-triggered AKI. Here, we reported miR-186 was considerably decreased in the serum samples from AKI patients compared with those from the healthy controls. Additionally, we found in NRK-52E cells exposed to 6 mM cisplatin, miR-186 was greatly decreased time-dependently. Meanwhile, an AKI model in rats was successfully set in our study. Levels of serum creatinine and blood urea nitrogen were significantly induced by cisplatin exposure. In AKI rat models, miR-186 exhibited a rapid decrease in both the serum and the kidney tissues. Then, miR-186 overexpression improved NRK-52E cell proliferation and protected NRK-52E cells against cisplatin-triggered apoptosis. Furthermore, ZEB1 was identified and confirmed as a target gene of miR-186. It has been demonstrated that ZEB1 exerts crucial roles in the development of AKI. As evidenced in our current study, ZEB1 was remarkably elevated in AKI patients and AKI rat models. Moreover, ZEB1 was induced by indicated doses of cisplatin in different time periods in NRK-52E cells. ZEB1 inhibition rescued the reduced proliferation and increased apoptosis of NRK-52E cells. In conclusion, loss miR-186 expression contributed to cisplatin-induced AKI, partly through targeting ZEB1. miR-186 might be provided as an effective biomarker for AKI via targeting ZEB1.
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
FOXO3a Protects against Kidney Injury in Type II Diabetic Nephropathy by Promoting Sirt6 Expression and Inhibiting Smad3 Acetylation
Diabetic nephropathy (DN) is the most common cause of end‐stage renal disease. Although numerous reports have demonstrated a correlation between epithelial‐mesenchymal transition (EMT) and renal fibrosis, how these processes lead to tubular dysfunction remains unclear. Here, we show that FOXO3a protects kidneys from injury in type II DN by increasing Sirt6 expression, which deacetylates Smad3 and inhibits its transcriptional activity. The results showed that progressive EMT in the kidneys from db/db mice is associated with Sirt6 downregulation and involved in tubular injury and dysfunction. The reduction of Sirt6 levels in db/db mice resulted in progressive kidney injury, indicating the protective role of Sirt6. Furthermore, Sirt6 was shown to directly bind to Smad3, a key downstream mediator of TGF‐β, and could deacetylate it to inhibit its nuclear accumulation and transcriptional activity in HK2 cells. Besides, we demonstrate that FOXO3a activates Sirt6 expression by binding to its promoter. shRNA‐induced FOXO3a knockdown in the kidneys of db/db mice exacerbated tubular injury and renal function loss. Mechanistically, FOXO3a protects against kidney injury in type II DN through the Sirt6/Smad3 axis. Thus, the pharmacological targeting of FOXO3a‐mediated Sirt6/Smad3 signaling pathways may provide a novel strategy for treating type II DN.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessFOXO3a Protects against Kidney Injury in Type II Diabetic Nephropathy by Promoting Sirt6 Expression and Inhibiting Smad3 Acetylation
Diabetic nephropathy (DN) is the most common cause of end‐stage renal disease. Although numerous reports have demonstrated a correlation between epithelial‐mesenchymal transition (EMT) and renal fibrosis, how these processes lead to tubular dysfunction remains unclear. Here, we show that FOXO3a protects kidneys from injury in type II DN by increasing Sirt6 expression, which deacetylates Smad3 and inhibits its transcriptional activity. The results showed that progressive EMT in the kidneys from db/db mice is associated with Sirt6 downregulation and involved in tubular injury and dysfunction. The reduction of Sirt6 levels in db/db mice resulted in progressive kidney injury, indicating the protective role of Sirt6. Furthermore, Sirt6 was shown to directly bind to Smad3, a key downstream mediator of TGF‐β, and could deacetylate it to inhibit its nuclear accumulation and transcriptional activity in HK2 cells. Besides, we demonstrate that FOXO3a activates Sirt6 expression by binding to its promoter. shRNA‐induced FOXO3a knockdown in the kidneys of db/db mice exacerbated tubular injury and renal function loss. Mechanistically, FOXO3a protects against kidney injury in type II DN through the Sirt6/Smad3 axis. Thus, the pharmacological targeting of FOXO3a‐mediated Sirt6/Smad3 signaling pathways may provide a novel strategy for treating type II DN.
- Open Access
- 24 November 2020
- Published by Impact Journals, LLC in Aging
- Vol. 13 (1) , 340-350
LINC00052 ameliorates acute kidney injury by sponging miR-532-3p and activating the Wnt signaling pathway
Acute kidney injury (AKI) is a complex renal disease. Long non-coding RNAs (lncRNAs) have frequently been associated with AKI. In the present study, we aimed to investigate the molecular mechanism(s) of LINC00052 in AKI. We found that LINC00052 expression was significantly decreased in AKI patient serum. In addition, in a hypoxic AKI cell model, LINC00052 expression was strongly elevated. In an I/R-triggered AKI rat model, the expression of TNF-α, IL-6 and IL-1β mRNA was strongly elevated. Moreover, we predicted miR-532-3p to be targeted by LINC00052 in AKI. Overexpression of LINC00052 increased hypoxia-induced inhibition of NRK-52E cell proliferation and reversed hypoxia-triggered apoptosis. Furthermore, we found that induction of TNF-α, IL-6 and IL-1β was repressed by overexpression of LINC00052. LINC00052 decreased hypoxia-induced ROS and MDA accumulation in vitro and increased SOD activity. Decreased levels of c-myc and cyclin D1 were observed in renal tissues of AKI rats. Lastly, Wnt/β-catenin signaling was inactivated in NRK-52E cells experiencing hypoxia, and LINC00052 upregulation reactivated Wnt/β-catenin signaling by sponging miR-532-3p. Taken together, these results suggest that LINC00052 ameliorates AKI by sponging miR-532-3p and activating Wnt signaling.
- 24 November 2020
- Published by Impact Journals, LLC in Aging
- Vol. 13 (1) , 340-350
Open AccessLINC00052 ameliorates acute kidney injury by sponging miR-532-3p and activating the Wnt signaling pathway
Acute kidney injury (AKI) is a complex renal disease. Long non-coding RNAs (lncRNAs) have frequently been associated with AKI. In the present study, we aimed to investigate the molecular mechanism(s) of LINC00052 in AKI. We found that LINC00052 expression was significantly decreased in AKI patient serum. In addition, in a hypoxic AKI cell model, LINC00052 expression was strongly elevated. In an I/R-triggered AKI rat model, the expression of TNF-α, IL-6 and IL-1β mRNA was strongly elevated. Moreover, we predicted miR-532-3p to be targeted by LINC00052 in AKI. Overexpression of LINC00052 increased hypoxia-induced inhibition of NRK-52E cell proliferation and reversed hypoxia-triggered apoptosis. Furthermore, we found that induction of TNF-α, IL-6 and IL-1β was repressed by overexpression of LINC00052. LINC00052 decreased hypoxia-induced ROS and MDA accumulation in vitro and increased SOD activity. Decreased levels of c-myc and cyclin D1 were observed in renal tissues of AKI rats. Lastly, Wnt/β-catenin signaling was inactivated in NRK-52E cells experiencing hypoxia, and LINC00052 upregulation reactivated Wnt/β-catenin signaling by sponging miR-532-3p. Taken together, these results suggest that LINC00052 ameliorates AKI by sponging miR-532-3p and activating Wnt signaling.
- Open Access
- 23 November 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (11) , 1-13
Exosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF-κB/MMP-2 axis
Diabetic kidney disease (DKD) is closely associated with the high risk of cardiovascular disease and mortality. Exosomal circRNAs can exert significant roles in the pathology of various diseases. Nevertheless, the role of exosomal circRNAs in DKD progression remains barely known. Circular RNA DLGAP4 has been reported to be in involved in acute ischemic stroke. In our study, we found exosomal circ_DLGAP4 was increased in the exosomes isolated from HG-treated mesangial cells (MCs), DKD patients, and DKD rat models compared with the corresponding normal subjects. Then, we observed that exo-circ_DLGAP4 significantly promoted proliferation and fibrosis of MCs cells. Moreover, to study the underlying mechanism of circ_DLGAP4 in regulating DKD, bioinformatics method was consulted and miR-143 was predicted as its target. The direct correlation between miR-143 and circ_DLGAP4 was validated in MCs. MCs proliferation and fibrosis were increased by circ_DLGAP4, which could be decreased by mimic-miR-143. Next, elevated expression of Erb-b2 receptor tyrosine kinase 3 (ERBB3) is involved in various diseases. However, the function of ERBB3 in DKD development remains poorly known. Next, ERBB3 was predicted as the downstream target for miR-143. It was displayed that circ_DLGAP4 promoted proliferation and fibrosis of MCs by sponging miR-143 and regulating ERBB3/NF-κB/MMP-2 axis. Meanwhile, the loss of exo-circ_DLGAP4 induced miR-143 and repressed ERBB3/NF-κB/MMP-2 expression in MCs. Subsequently, in vivo assays were performed and it was proved that overexpression of circ_DLGAP4 markedly promoted DKD progression in vivo via modulating miR-143/ERBB3/NF-κB/MMP-2. In conclusion, we indicated that exosomal circ_DLGAP4 could prove a novel insight for DKD development.
- 23 November 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (11) , 1-13
Open AccessExosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF-κB/MMP-2 axis
Diabetic kidney disease (DKD) is closely associated with the high risk of cardiovascular disease and mortality. Exosomal circRNAs can exert significant roles in the pathology of various diseases. Nevertheless, the role of exosomal circRNAs in DKD progression remains barely known. Circular RNA DLGAP4 has been reported to be in involved in acute ischemic stroke. In our study, we found exosomal circ_DLGAP4 was increased in the exosomes isolated from HG-treated mesangial cells (MCs), DKD patients, and DKD rat models compared with the corresponding normal subjects. Then, we observed that exo-circ_DLGAP4 significantly promoted proliferation and fibrosis of MCs cells. Moreover, to study the underlying mechanism of circ_DLGAP4 in regulating DKD, bioinformatics method was consulted and miR-143 was predicted as its target. The direct correlation between miR-143 and circ_DLGAP4 was validated in MCs. MCs proliferation and fibrosis were increased by circ_DLGAP4, which could be decreased by mimic-miR-143. Next, elevated expression of Erb-b2 receptor tyrosine kinase 3 (ERBB3) is involved in various diseases. However, the function of ERBB3 in DKD development remains poorly known. Next, ERBB3 was predicted as the downstream target for miR-143. It was displayed that circ_DLGAP4 promoted proliferation and fibrosis of MCs by sponging miR-143 and regulating ERBB3/NF-κB/MMP-2 axis. Meanwhile, the loss of exo-circ_DLGAP4 induced miR-143 and repressed ERBB3/NF-κB/MMP-2 expression in MCs. Subsequently, in vivo assays were performed and it was proved that overexpression of circ_DLGAP4 markedly promoted DKD progression in vivo via modulating miR-143/ERBB3/NF-κB/MMP-2. In conclusion, we indicated that exosomal circ_DLGAP4 could prove a novel insight for DKD development.